Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Unknown 2Available 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 5NIH 1

Study Type

Interventional 4Expanded_access 2

Sponsor

Cancer Type

Genitourinary 2Tumor-Agnostic 1Other 1Gastrointestinal 1CNS 1

Conditions

Prostatic Neoplasms 1Prostate Cancer Recurrent 1Ototoxicity 1Neoplasm Metastasis 1Mucositis 1Glioblastoma 1Dermatitis 1Anus Neoplasms 1

Interventions

Cisplatin 3193Cyclophosphamide 3187Carboplatin 2968Radiotherapy 2784Paclitaxel 2716Gemcitabine 2569pembrolizumab 2378Bevacizumab 2206Docetaxel 2196Fluorouracil 1848Capecitabine 1828Oxaliplatin 1738Dexamethasone 1604Nivolumab 1580Doxorubicin 1501Rituximab 1487Magnetic Resonance Spectroscopy 1382Etoposide 1345Irinotecan 1245Leucovorin 1222Drug Therapy 1202Cytarabine 1130Pemetrexed 1074fludarabine 1056Specimen Handling 1009Vincristine 964Cetuximab 943Prednisone 940Trastuzumab 940Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
tempol × Clear all
NCT03480971 2024-11-20

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

Matrix Biomed, Inc.

Phase 2 Recruiting
120 enrolled
Other

Ototoxicity, Mucositis

NCT05491928 2022-09-01

Treatment of Metastatic Cancer in Terminally Diagnosed Patients

Matrix Biomed, Inc.

Available
Tumor-Agnostic

Neoplasm Metastasis

NCT01324141 2021-11-23

Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
6 enrolled 28 charts
Gastrointestinal

Anus Neoplasms, Dermatitis

NCT04876755 2021-05-06

MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer

Matrix Biomed, Inc.

Phase 2 Unknown
55 enrolled
Genitourinary

Prostate Cancer Recurrent

NCT04337099 2021-05-05

A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer

Matrix Biomed, Inc.

Available
Genitourinary

Prostatic Neoplasms

NCT04874506 2021-05-05

MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)

Matrix Biomed, Inc.

Phase 2 Unknown
55 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡